Compare PRME & TALK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRME | TALK |
|---|---|---|
| Founded | 2019 | 2012 |
| Country | United States | United States |
| Employees | N/A | 521 |
| Industry | Medicinal Chemicals and Botanical Products | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 536.4M | 788.5M |
| IPO Year | 2022 | N/A |
| Metric | PRME | TALK |
|---|---|---|
| Price | $3.54 | $5.19 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 6 |
| Target Price | ★ $7.56 | $6.42 |
| AVG Volume (30 Days) | ★ 2.5M | 1.3M |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.18 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,632,000.00 | N/A |
| Revenue This Year | $7.06 | $26.02 |
| Revenue Next Year | $47.01 | $21.24 |
| P/E Ratio | ★ N/A | $155.55 |
| Revenue Growth | ★ 55.28 | N/A |
| 52 Week Low | $1.18 | $2.22 |
| 52 Week High | $6.94 | $5.20 |
| Indicator | PRME | TALK |
|---|---|---|
| Relative Strength Index (RSI) | 59.16 | 55.78 |
| Support Level | $3.15 | $4.59 |
| Resistance Level | $3.60 | $5.20 |
| Average True Range (ATR) | 0.23 | 0.01 |
| MACD | 0.07 | -0.00 |
| Stochastic Oscillator | 93.44 | 50.50 |
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
Talkspace Inc is a behavioral healthcare company offering access to licensed therapists, psychologists, and psychiatrists through its technology platform. It serves clients including health plans, enterprises, and individual subscribers. Therapists address various mental health conditions, while psychiatrists cater to a higher acuity demographic. Revenue stems from payor and direct-to-enterprise clients, with contracts lasting one to three years. The majority of the Company's operations and revenues are based in the United States.